Sodium Salicylate

A cell-permeable, non-steroidal anti-inflammatory agent that interferes with TNF-induced NF-κB activation by inhibiting phosphorylation and subsequent degradation of the IκB-α protein. Selectively inhibits TNF-induced activation of p42 (ERK2) and p44 (ERK1) MAP kinases. Also inhibits TNF-induced activation of JNK. Induces apoptosis via p38 kinase activation. Inhibits COX-2 and inducible NOS (iNOS) transcription independently of NF-κB activation.

A non-steroidal, anti-inflammatory drug that interferes with TNF-induced NF-κB activation by inhibiting phosphorylation and subsequent degradation of the IκB-α protein. Selectively inhibits TNF-induced activation of p42 (ERK2) and p44 (ERK1) MAP kinases. Also inhibits TNF-induced activation of JNK. Induces apoptosis via p38 kinase activation. Inhibits COX-2 and inducible NOS (iNOS) transcription independently of NF-κB activation.

Cell permeable: yes

Primary Target
TNF-induced activation of p42 (ERK2) and p44 (ERK1) MAP kinases

Product does not compete with ATP.

Reversible: no

Packaged under inert gas

Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months at -20°C.

Schwenger, P., et al. 1998. Mol. Cell. Biol. 18, 78.
Mitchell, J.A., et al. 1997. Mol. Pharmacol. 51, 907.
Schwenger, P., et al. 1997. Proc. Natl. Acad. Sci. USA 94, 2869.
Farivar, R.S. and Brecher, P. 1996. J. Biol. Chem. 271, 31585.
Schwenger, P., et al. 1996. J. Biol. Chem. 271, 8089.

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Toxicity: Harmful (C)